Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 6/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | MGLL | Q99685 | 1/20 | 0.36 |
| ▸ | BCL2L2 | Q92843 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 2/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2674495 | 0.77 | MMP12 (0.46) | CYP3A4MMP13 | |
| SCHEMBL2675488 | 0.76 | CYP4A11 (0.49) | CYP3A4TSHRALDH1A1HSD17B10MGLL | |
| SCHEMBL9770144 | 0.76 | CYP3A4 (0.47) | CYP3A4CASP1TSHRALDH1A1HSD17B10 | |
| SCHEMBL10348290 | 0.75 | CYP3A4 (0.46) | CYP3A4CASP1TSHRALDH1A1HSD17B10 | |
| SCHEMBL8697093 | 0.75 | CYP3A4 (0.46) | CYP3A4CASP1TSHRALDH1A1HSD17B10 | |
| SCHEMBL4711848 | 0.75 | CYP3A4 (0.46) | CYP3A4CASP1TSHRALDH1A1HSD17B10 | |
| Hydrochloric Acid SCHEMBL14332245 | 0.73 | CYP3A4 (0.45) | CYP3A4CASP1TSHRALDH1A1HSD17B10 | |
| SCHEMBL14331820 | 0.73 | CYP3A4 (0.51) | CYP3A4CASP1TSHRALDH1A1HSD17B10 | |
| SCHEMBL29558885 | 0.72 | FAAH (0.50) | CYP3A4CASP1TSHRFAAHMGLL | |
| SCHEMBL8517163 | 0.72 | CTSS (0.35) | CYP3A4TSHRALDH1A1HSD17B10SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173704-B2 | Difluorophenol derivatives and their use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-05-08 | — | — | US | disclosed |
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291993-A1 | Difluorophenol Derivatives and Their Use | TPMT, FABP3, DPP4 | CYP3A4 178/4885CASP1 2230/4885TSHR 1729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.